	Les Charges D'Exploitation		Date
Abbott	USD 9.21B	17M	2025-12
Acadia Pharmaceuticals	USD 242.88M	10.68M	2025-09
Agios Pharmaceuticals	USD 129.75M	9.76M	2025-09
Akebia Therapeutics	USD 43.82M	16.98M	2025-03
Alnylam Pharmaceuticals	USD 881.04M	91.16M	2025-09
AstraZeneca	USD 12.53B	4.16B	2025-12
BioMarin Pharmaceutical	USD 807.82M	259.3M	2025-09
Coherus Biosciences	USD 53.03M	43.41M	2025-03
Eli Lilly	USD 10.31B	1.09B	2025-12
Esperion Therapeutics	USD 67.66M	3.6M	2024-09
Halozyme Therapeutics	USD 136.34M	13.06M	2025-09
Illumina	USD 903M	69M	2025-12
Insmed	USD 403.69M	42.4M	2025-09
Ironwood Pharmaceuticals	USD 57.33M	8.63M	2024-12
J&J	USD 18.97B	2.38B	2025-12
Lexicon Pharmaceuticals	USD 57M	10.54M	2024-06
MacroGenics	USD 67M	8M	2025-09
MannKind	USD 63.35M	2.51M	2025-09
Merck	USD 10.16B	558M	2025-12
Moderna	USD 1.28B	232M	2025-09
Novartis	USD 9.86B	115M	2025-09
PTC Therapeutics	USD 207.52M	6.21M	2025-09
Puma Biotechnology	USD 49.26M	3.2M	2024-06
Sarepta Therapeutics	USD 462.23M	33.28M	2025-09
Thermo Fisher Scientific	USD 9.91B	867M	2025-12
Ultragenyx Pharmaceutical	USD 330.82M	56.44M	2025-09
United Therapeutics	USD 6.59B	6.07B	2025-09
Vanda Pharmaceuticals	USD 466M	20.33M	2025-09

Lexicon Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.